Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03239145 · OUTCOME

Grade 3 or Higher Toxicity Rate in Expansion Cohort

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor · Source last updated 2026-07-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
90% Confidence Interval
Time frame
The median follow up time was 3.3 months (range: 0.6 to 25.3 months).

What was measured

The percentage of participants who experienced grade 3 or higher adverse event based on the Common Toxicity Criteria for Adverse Events Version 4.0 (CTCAEv4).

Analysis population: This analysis only included participants enrolled and treated during the dose expansion period.

Groups in this outcome

[Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal)

Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.

Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian)

Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly

Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)

Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
[Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal)37
Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian)11
Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)4

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
[Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal)59.5Not reported44.673.1Not reported
Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian)63.6Not reported35.086.5Not reported
Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)75.0Not reported24.998.7Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        44.6
        upper Limit
        73.1
        value
        59.5
      2. group Id
        OG001
        lower Limit
        35.0
        upper Limit
        86.5
        value
        63.6
      3. group Id
        OG002
        lower Limit
        24.9
        upper Limit
        98.7
        value
        75.0
denoms
  1. counts
    1. group Id
      OG000
      value
      37
    2. group Id
      OG001
      value
      11
    3. group Id
      OG002
      value
      4
    units
    Participants
description
The percentage of participants who experienced grade 3 or higher adverse event based on the Common Toxicity Criteria for Adverse Events Version 4.0 (CTCAEv4).
dispersion Type
90% Confidence Interval
groups
  1. description
    Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.
    id
    OG000
    title
    [Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal)
  2. description
    Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly
    id
    OG001
    title
    Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian)
  3. description
    Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.
    id
    OG002
    title
    Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)
param Type
NUMBER
population Description
This analysis only included participants enrolled and treated during the dose expansion period.
reporting Status
POSTED
time Frame
The median follow up time was 3.3 months (range: 0.6 to 25.3 months).
title
Grade 3 or Higher Toxicity Rate in Expansion Cohort
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice